Carboxylesterases: General detoxifying enzymes

Chemico-Biological Interactions

Volumn 259, Issue , 2016, Pages 327-331

  Hatfield, M Jason ^a   Umans, Robyn A ^a   Hyatt, Janice L ^a   Edwards, Carol C ^a   Wierdl, Monika ^a   Tsurkan, Lyudmila ^a   Taylor, Michael R ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Carboxylesterase; Expression; Hydrolysis; Organophosphorus compounds; Structure

Indexed keywords

4 NITROPHENYL PHOSPHATE; CARBOXYLESTERASE; CLOPIDOGREL; COCAINE; CYCLOSARIN; DIAMORPHINE; FLUORESCEIN DIACETATE; METHYLPHENIDATE; ORGANOPHOSPHATE; OSELTAMIVIR; PERMETHRIN; PETHIDINE; PROCAINE; QUINAPRIL; SOMAN; TABUN; TEMOCAPRIL;

ARTICLE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DRUG INACTIVATION; METABOLISM; MOLECULAR MODEL;

ANIMALS; CARBOXYLIC ESTER HYDROLASES; HUMANS; INACTIVATION, METABOLIC; MODELS, MOLECULAR; ORGANOPHOSPHATES; SUBSTRATE SPECIFICITY;

EID: 84959441050     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2016.02.011     Document Type: Article

References (26)

1. [1] Loevenhart, A.S., Further observations on the action of lipase. Am. J. Physiol., 15, 1906, 27.
2. [2] Cashman, J., Perroti, B., Berkman, C., Lin, J., Pharmacokinetics and molecular detoxification. Environ. Health Perspect. 104 (1996), 23–40.
3. [3] Satoh, T., Hosokawa, M., The mammalian carboxylesterases: from molecules to function. Annu. Rev. Pharmacol. Toxicol. 38 (1998), 257–288.
4. [4] Bencharit, S., Edwards, C.C., Morton, C.L., Howard-Williams, E.L., Kuhn, P., Potter, P.M., Redinbo, M.R., Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J. Mol. Biol. 363 (2006), 201–214.
5. [5] Bencharit, S., Morton, C.L., Howard-Williams, E.L., Danks, M.K., Potter, P.M., Redinbo, M.R., Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat. Struct. Biol. 9 (2002), 337–342.
6. [6] Bencharit, S., Morton, C.L., Hyatt, J.L., Kuhn, P., Danks, M.K., Potter, P.M., Redinbo, M.R., Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine. From binding promiscuity to selective inhibition. Chem. Biol. 10 (2003), 341–349.
7. [7] Bencharit, S., Morton, C.L., Xue, Y., Potter, P.M., Redinbo, M.R., Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 10 (2003), 349–356.
8. [8] Wierdl, M., Tsurkan, L., Hyatt, J.L., Edwards, C.C., Hatfield, M.J., Morton, C.L., Houghton, P.J., Danks, M.K., Redinbo, M.R., Potter, P.M., An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther. 15 (2008), 183–192.
9. [9] Hamilton, S.E., Dudman, A.P., De Jersey, J., Stoops, J.K., Zerner, B., Organophosphate inhibitors: the reactions of bis(p-nitrophenyl) methyl phosphate with liver carboxylesterases and alpha-chymotrypsin. Biochim. Biophys. Acta. 377 (1975), 282–296.
10. [10] Cohen, S.D., Ehrich, M., Cholinesterase and carboxylesterase inhibition by dichlorvos and interactions with malathion and triorthotolyl phosphate. Toxicol. Appl. Pharmacol. 37 (1976), 39–48.
11. [11] Maxwell, D.M., The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds. Toxicol. Appl. Pharmacol. 114 (1992), 306–312.
12. [12] Hatfield, M.J., Tsurkan, L., Garrett, M., Shaver, T., Edwards, C.C., Hyatt, J.L., Hicks, L.D., Potter, P.M., Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem. Pharmacol. 81 (2011), 24–31.
13. [13] Williams, F.M., Potential for metabolism locally in the skin of dermally absorbed compounds. Hum. Exp. Toxicol. 27 (2008), 277–280.
14. [14] Li, B., Sedlacek, M., Manoharan, I., Boopathy, R., Duysen, E.G., Masson, P., Lockridge, O., Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 70 (2005), 1673–1684.
15. [15] Morton, C.L., Iacono, L., Hyatt, J.L., Taylor, K.R., Cheshire, P.J., Houghton, P.J., Danks, M.K., Stewart, C.F., Potter, P.M., Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol. 56 (2005), 629–636.
16. [16] Morton, C.L., Wierdl, M., Oliver, L., Ma, M., Danks, M.K., Stewart, C.F., Eiseman, J.L., Potter, P.M., Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase. Cancer Res. 60 (2000), 4206–4210.
17. [17] Guemei, A.A., Cottrell, J., Band, R., Hehman, H., Prudhomme, M., Pavlov, M.V., Grem, J.L., Ismail, A.S., Bowen, D., Taylor, R.E., Takimoto, C.H., Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother. Pharmacol. 47 (2001), 283–290.
18. [18] Potter, P.M., Wolverton, J.S., Morton, C.L., Whipple, D.O., Danks, M.K., In situ subcellular localization of epitope tagged human and rabbit carboxylesterases. Cytometry 32 (1998), 223–232.
19. [19] Potter, P.M., Wolverton, J.S., Morton, C.L., Wierdl, M., Danks, M.K., Cellular localization domains of a rabbit and a human carboxylesterase: Influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res. 58 (1998), 3627–3632.
20. [20] Fleming, C.D., Bencharit, S., Edwards, C.C., Hyatt, J.L., Tsurkan, L., Bai, F., Fraga, C., Morton, C.L., Howard-Williams, E.L., Potter, P.M., Redinbo, M.R., Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J. Mol. Biol. 352 (2005), 165–177.
21. [21] Redinbo, M.R., Potter, P.M., Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov. Today 10 (2005), 313–325.
22. [22] Wadkins, R.M., Hyatt, J.L., Yoon, K.J., Morton, C.L., Lee, R.E., Damodaran, K., Beroza, P., Danks, M.K., Potter, P.M., Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol. Pharmacol. 65 (2004), 1336–1343.
23. [23] Wadkins, R.M., Hyatt, J.L., Wei, X., Yoon, K.J., Wierdl, M., Edwards, C.C., Morton, C.L., Obenauer, J.C., Damodaran, K., Beroza, P., Danks, M.K., Potter, P.M., Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J. Med. Chem. 48 (2005), 2905–2915.
24. [24] Hemmert, A.C., Otto, T.C., Chica, R.A., Wierdl, M., Edwards, J.S., Lewis, S.L., Edwards, C.C., Tsurkan, L., Cadieux, C.L., Kasten, S.A., Cashman, J.R., Mayo, S.L., Potter, P.M., Cerasoli, D.M., Redinbo, M.R., Nerve agent hydrolysis activity designed into a human drug metabolism enzyme. PloS One, 6, 2011, e17441.
25. [25] Fleming, C.D., Edwards, C.C., Kirby, S.D., Maxwell, D.M., Potter, P.M., Cerasoli, D.M., Redinbo, M.R., Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. Biochemistry 46 (2007), 5063–5071.
26. [26] Hemmert, A.C., Otto, T.C., Wierdl, M., Edwards, C.C., Fleming, C.D., MacDonald, M., Cashman, J.R., Potter, P.M., Cerasoli, D.M., Redinbo, M.R., Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin. Mol. Pharmacol. 77 (2010), 508–516.